Boehringer Ingelheim: Christine Sakdalan and Michael Jablonski

🎧 Leaders at Boehringer Ingelheim on Precision Psychiatry

In this episode of Power to the Patients, Christine Sakdalan (US Therapeutic Area Head, Mental Health Franchise) and Michael Jablonski (VP of Clinical Development & Medical Affairs, CNS & Retinal Health) from Boehringer Ingelheim discuss the evolving role of precision psychiatry in clinical research.

The conversation focuses on how tools like EEGs, neuroimaging, and AI are being explored to better match patients to treatments and reduce inefficiencies in psychiatric trials. Sakdalan and Jablonski also share perspectives on applying a more individualized approach to conditions such as schizophrenia.

Key discussion points include:

• Using biological data to guide recruitment and care decisions
• Opportunities for AI to support treatment prediction and trial optimization
• How a personalized approach could affect study design and endpoints

🎧 Listen to the episode on Apple | Spotify

‍